Assessment of Novel Measurement and Fitting Methods to Determine Their Reliability, Validity and Application – Sonova2018_34

Overview

A methodical evaluation of novel measurement and fitting methods for individualizing CE-labelled Sonova brand hearing instruments (e.g. Phonak hearing instruments) is intended to be conducted on hearing impaired participants. The aim of the study is to investigate and asses strength and weaknesses of these novel measurement and fitting methods in terms of optimizing hearing performance and experience and/or usability of the hearing aids and accessories. Both laboratory measurements as well as evaluations in real life environments will be carried out. This will be a controlled and randomised active comparator clinical evaluation which will be conducted mono-centric at Sonova AG Headquarter based in Stäfa.

Full Title of Study: “Assessment of Novel Measurement and Fitting Methods to Determine Their Reliability, Validity and Application”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: January 31, 2019

Interventions

  • Device: Hearing aid: Phonak Audéo B90-Direct
    • Hearing aids will be fitted to the participants individual hearing loss.

Arms, Groups and Cohorts

  • Active Comparator: Audéo B-Direct fitted with fitting method A
    • Traditional standard fitting method which do not include adjustments from the participants.
  • Experimental: Audéo B-Direct fitted with fitting method B
    • Alternative fitting method which includes additional adjustments from the participants.

Clinical Trial Outcome Measures

Primary Measures

  • Comparison of fitting method A versus B in regard to sound quality
    • Time Frame: 2 months
    • The number of subjects who prefer the hearing aid setting achieved with hearing aid fitting method A versus B will be measured in the lab with the aid of sounds presented via loudspeakers. This will be measured with the Multiple Stimuli with Hidden Reference and Anchor (MUSHRA) method.

Secondary Measures

  • Comparison of fitting method A versus B in regard to speech intelligibility in noise
    • Time Frame: 2 months
    • The speech intelligibility in noise with hearing aid fitting method A versus B will be measured with the aid of the Oldenburg sentence test in dB Speech Reception Treshold (SRT).

Participating in This Clinical Trial

Participants fulfilling all of the following inclusion criteria are eligible for the study:

  • Adult hearing impaired persons (minimum age: 18 years) with and without (experience with) hearing aids – Healthy outer ear (without previous surgical procedures) – Ability to fill in a questionnaire (p/eCRF) conscientiously – Informed Consent as documented by signature The presence of any one of the following exclusion criteria will lead to exclusion of the participant: – Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product – Limited mobility and not in the position to attend appointments – Limited ability to describe listening impressions or to use hearing aids/ accessories – Inability to produce a reliable hearing test result – Massively limited dexterity – Known psychological problems – Known central hearing disorders

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sonova AG
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.